ストックスクリーナーアプリを入手
19.85
7.30%
1.35
アフターアワーズ：
19.98
0.13
+0.65%
前日終値:
$18.50
開ける：
$18.75
24時間の取引高:
1.87M
Relative Volume:
0.67
時価総額：
$1.92B
収益：
$672.72M
当期純損益:
$-575.44M
株価収益率:
-3.4012
EPS:
-5.8361
ネットキャッシュフロー:
$-487.00M
1週間 パフォーマンス:
-2.98%
1か月 パフォーマンス:
-13.36%
6か月 パフォーマンス:
-28.65%
1年 パフォーマンス:
-48.69%
1日の値動き範囲:
$18.70
$19.94
1週間の範囲:
$18.29
$20.68
52週間の値動き範囲:
$18.29
$42.37
Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile
名前
Ultragenyx Pharmaceutical Inc
セクター
電話
415-483-8800
住所
60 LEVERONI COURT, NOVATO, CA
Compare RARE vs VRTX, REGN, ALNY, ARGX, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RARE
Ultragenyx Pharmaceutical Inc
|
19.85 | 1.79B | 672.72M | -575.44M | -487.00M | -5.8361 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
750.07 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-20 | 開始されました | Wells Fargo | Overweight |
| 2025-07-28 | 再開されました | H.C. Wainwright | Buy |
| 2025-05-28 | 開始されました | William Blair | Outperform |
| 2024-06-06 | アップグレード | Goldman | Neutral → Buy |
| 2024-04-22 | 開始されました | RBC Capital Mkts | Outperform |
| 2023-12-08 | 開始されました | Wells Fargo | Overweight |
| 2023-06-14 | 再開されました | Credit Suisse | Outperform |
| 2023-06-06 | アップグレード | Evercore ISI | In-line → Outperform |
| 2023-04-26 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-01-18 | 再開されました | Canaccord Genuity | Buy |
| 2022-12-30 | 再開されました | H.C. Wainwright | Buy |
| 2022-11-03 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2022-10-13 | アップグレード | Guggenheim | Neutral → Buy |
| 2022-08-01 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2022-03-16 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2022-02-11 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-09-30 | 開始されました | H.C. Wainwright | Buy |
| 2021-08-19 | 開始されました | UBS | Sell |
| 2021-07-15 | 開始されました | Guggenheim | Neutral |
| 2021-06-29 | アップグレード | BofA Securities | Neutral → Buy |
| 2021-06-04 | 再開されました | Robert W. Baird | Neutral |
| 2021-05-06 | アップグレード | Citigroup | Neutral → Buy |
| 2021-05-06 | アップグレード | Evercore ISI | In-line → Outperform |
| 2021-04-26 | 再開されました | Credit Suisse | Neutral |
| 2021-03-02 | 再開されました | Stifel | Buy |
| 2021-02-12 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-12-07 | ダウングレード | Wedbush | Outperform → Neutral |
| 2020-11-24 | 再開されました | Evercore ISI | In-line |
| 2020-11-12 | ダウングレード | BofA Securities | Buy → Neutral |
| 2019-08-02 | 再開されました | Wedbush | Outperform |
| 2019-03-27 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2019-02-22 | 再開されました | Raymond James | Outperform |
| 2019-01-02 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2018-11-08 | アップグレード | Citigroup | Sell → Neutral |
| 2018-09-10 | 開始されました | Morgan Stanley | Equal-Weight |
| 2018-06-21 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2018-05-11 | アップグレード | Barclays | Equal Weight → Overweight |
| 2018-05-10 | 開始されました | Goldman | Neutral |
| 2018-04-18 | アップグレード | SunTrust | Hold → Buy |
| 2018-03-22 | 再開されました | Piper Jaffray | Overweight |
| 2018-02-21 | 繰り返されました | Stifel | Buy |
| 2018-01-22 | アップグレード | Evercore ISI | In-line → Outperform |
| 2018-01-18 | 開始されました | Credit Suisse | Outperform |
| 2017-12-05 | 繰り返されました | Barclays | Equal Weight |
| 2017-12-04 | アップグレード | Jefferies | Hold → Buy |
| 2017-09-14 | アップグレード | Wedbush | Neutral → Outperform |
すべてを表示
Ultragenyx Pharmaceutical Inc (RARE) 最新ニュース
RARE Investor Alert: Ultragenyx Pharmaceutical Inc. Stockholders with Large Losses Should Contact Robbins LLP for Information About the Securities Fraud Class Action Lawsuit - The AI Journal
Ultragenyx Nears Key Inflection Point With Completed Phase 3 Gene Therapy Study in GSDIa - TipRanks
Bronstein, Gewirtz & Grossman LLC Urges Ultragenyx Pharmaceutical Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire Inc.
Lost Money on Ultragenyx Pharmaceutical Inc.(RARE)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - Morningstar
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Q4 2025 earnings call transcript - MSN
Momentum Shift: Will Ultragenyx Pharmaceutical Inc outperform tech stocksGold Moves & Free Community Supported Trade Ideas - baoquankhu1.vn
Why Ultragenyx (RARE) Is Down 14.4% After Positive Phase 3 DTX301 Gene Therapy Results - simplywall.st
Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 - GlobeNewswire
Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - GlobeNewswire Inc.
Goldman Sachs Downgrades Ultragenyx (RARE), Slashes Price Target by 59% | RARE Stock News - GuruFocus
Goldman Sachs Downgrades Ultragenyx (RARE) Following Trial Setba - GuruFocus
Ultragenyx Pharmaceutical (NASDAQ:RARE) Sets New 1-Year Low After Analyst Downgrade - MarketBeat
Ultragenyx downgraded to neutral at Goldman Sachs on setrusumab data - Seeking Alpha
Ultragenyx stock hits 52-week low at 18.36 USD - Investing.com
Goldman Sachs downgrades Ultragenyx Pharma stock rating to neutral By Investing.com - Investing.com Australia
Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Rating Lowered by The Goldman Sachs Group - MarketBeat
Portnoy Law Firm Announces Class Action on Behalf of Ultragenyx Pharmaceutical, Inc. Investors - GlobeNewswire
Goldman Sachs Downgrades Ultragenyx Pharmaceutical to Neutral From Buy, Adjusts PT to $25 From $61 - marketscreener.com
Goldman Sachs downgrades Ultragenyx Pharma stock rating to neutral - Investing.com UK
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Investor Alert: Deadline in Lawsuit on April 6, 2026 - openPR.com
INVESTOR DEADLINE: Ultragenyx Pharmaceutical Inc. (RARE) - GlobeNewswire
RARE Investors Have Opportunity to Lead Ultragenyx - GlobeNewswire
RARE DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026 - Sahm
WOODSTOCK CORP's Ultragenyx Pharmaceutical Inc(RARE) Holding History - GuruFocus
Bronstein, Gewirtz & Grossman LLC Urges Ultragenyx - GlobeNewswire
2026-03-22 | RARE SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Ultragenyx Pharmaceutical Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! | NDAQ:RARE | Press Release - Stockhouse
Is It Time To Reconsider Ultragenyx Pharmaceutical (RARE) After A 47% One-Year Share Price Fall - Sahm
RARE DEADLINE NOTICE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Ultragenyx Pharmaceutical ... - Caledonian Record
RARE DEADLINE NOTICE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc.RARE - Sahm
How Ultragenyx Pharmaceutical Inc. (RARE) Affects Rotational Strategy Timing - Stock Traders Daily
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Two new Ultragenyx hires get 10,839 stock units under Nasdaq rule - Stock Titan
A Look At Ultragenyx Pharmaceutical’s Valuation After Recent Share Price Weakness - Yahoo Finance
Mucopolysaccharidosis Treatment Market to Reach US$6.76 - openPR.com
INVESTOR DEADLINE: Ultragenyx Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action LawsuitRGRD Law - Lelezard
Layoff Tracker: Gossamer, BiomX Reveal Hefty Staff Cuts - BioSpace
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit - ChartMill
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming DeadlinesRARE - PR Newswire
Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors - GlobeNewswire
RARE DEADLINE ALERT: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. ... - Caledonian Record
RARE DEADLINE ALERT: ROSEN, SKILLED INVESTOR COUNSEL, - GlobeNewswire
RARE CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) ... - Bluefield Daily Telegraph
LEVI & KORSINSKY, LLP: FRAUD-ON-THE-MARKET DOCTRINE UNDERPINS ULTRAGENYX PHARMACEUTICAL SECURITIES CLASS ACTION (2026-03-18) - Seeking Alpha
LEVI & KORSINSKY, LLP: FRAUD-ON-THE-MARKET DOCTRINE UNDERPINS ULTRAGENYX PHARMACEUTICAL SECURITIES CLASS ACTION - Sahm
INVESTOR DEADLINE: Ultragenyx Pharmaceutical Inc. Investors - GlobeNewswire
DTX301 Gene Therapy Lowers Ammonia Levels in Ornithine Transcarbamylase Deficiency at 36 Weeks - Neurology Live
RARE Shareholder Alert: Ultragenyx Pharmaceutical Inc. Securities Class Action Lawsuit Investors With Losses May Join -- The Gross Law Firm - PR Newswire
Aquatic Capital Management LLC Increases Holdings in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Phase 3 DTX301 Gene Therapy Data Could Be A Game Changer For Ultragenyx Pharmaceutical (RARE) - Sahm
RARE INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026 - PR Newswire
Ultragenyx Pharmaceutical Inc (RARE) 財務データ
収益
当期純利益
現金流量
EPS
Ultragenyx Pharmaceutical Inc (RARE) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Parschauer Karah Herdman | EVP and Chief Legal Officer |
Mar 10 '26 |
Sale |
22.67 |
3,508 |
79,526 |
66,820 |
1.86%
大文字化:
|
ボリューム (24 時間):